PFO
DWTX

Pathstone Family Office’s Dogwood Therapeutics DWTX Stock Holding History

Pathstone Family Office’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20
Closed -$4K – 1376
2020
Q4 		$4K Buy
+20
New +$4.82K ﹤0.01% 987

Other funds holding DWTX

MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
CA
Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pathstone Family Office's DWTX Position: Q1 2021 in Review

Pathstone Family Office sold out of Dogwood Therapeutics (DWTX) in Q1 2021, closing a stake of 20 shares — an estimated $4K sold.

Pathstone Family Office first reported a position in DWTX in Q4 2020 and held it in 1 quarter. The position peaked at $4K in Q4 2020. 14 funds tracked by Wall St. Rank hold DWTX as of Q1 2021.

  • Pathstone Family Office reported no remaining Dogwood Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Pathstone Family Office sold 20 Dogwood Therapeutics shares in Q1 2021, an estimated $4K.
  • Pathstone Family Office first reported a position in Dogwood Therapeutics in Q4 2020 and held it in 1 quarter.
  • Pathstone Family Office's Dogwood Therapeutics position peaked at $4K in Q4 2020.
  • 14 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.